Treatment coverage of the mass administration of azithromycin among 1-11 month olds in six states in Nigeria

Summary

Mass drug administration (MDA) with the antibiotic, azithromycin, is used for the treatment and prevention of blinding trachoma. Following the WHO conditional recommendation to conduct azithromycin MDA to children aged 1–11 months for the prevention of childhood mortality (in sub-Saharan African settings with infant mortality rate >60/1000 or/and under-5 mortality rate >80/1000), this publication documents implementation of MDA to children aged 1-11 months, using the trachoma MDA platform.

The authors report commendable coverage due to existing programme platform, healthcare and community structures, intensive advocacy and social mobilisation, real-time monitoring and progress-tracking strategies.